• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Jpn J Infect Dis . Transition of antibody titers after the SARS-CoV-2 mRNA vaccine in Japanese healthcare workers

tetano

Editor, Senior Moderator
Jpn J Infect Dis


. 2022 Aug 31.
doi: 10.7883/yoken.JJID.2022.041. Online ahead of print.
Transition of antibody titers after the SARS-CoV-2 mRNA vaccine in Japanese healthcare workers


Masahiro Kitabatake[SUP] 1 [/SUP], Noriko Ouji-Sageshima[SUP] 1 [/SUP], Shota Sonobe[SUP] 1 2 [/SUP], Ryutaro Furukawa[SUP] 1 3 [/SUP], Makiko Konda[SUP] 1 2 [/SUP], Atsushi Hara[SUP] 1 [/SUP], Hiroyasu Aoki[SUP] 4 [/SUP], Yuki Suzuki[SUP] 5 [/SUP], Natsuko Imakita[SUP] 3 [/SUP], Akiyo Nakano[SUP] 5 [/SUP], Yukio Fujita[SUP] 6 [/SUP], Shigeyuki Shichino[SUP] 4 [/SUP], Ryuichi Nakano[SUP] 5 [/SUP], Satoshi Ueha[SUP] 4 [/SUP], Kei Kasahara[SUP] 3 [/SUP], Shigeo Muro[SUP] 6 [/SUP], Hisakazu Yano[SUP] 5 [/SUP], Kouji Matsushima[SUP] 4 [/SUP], Toshihiro Ito[SUP] 1 [/SUP]



Affiliations

Abstract

Since February 2021, healthcare workers in Japan have been preferentially vaccinated with a messenger RNA vaccine (BNT162b2/Pfizer) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While many studies have confirmed that this vaccine is highly effective in reducing hospitalizations and deaths from coronavirus disease 2019 (COVID-19), antibody titers tend to decline at 3 months, leading to a risk of breakthrough infections. Thus, information is needed to support decision making regarding the third vaccination. In this study, we investigated transition of the anti-SARS-CoV-2 spike protein receptor-binding domain (RBD) IgG and neutralizing antibody titers of 37 vaccinated Japanese healthcare workers. Samples were collected six times starting prevaccination until 6 months after the second vaccination. Anti-SARS-CoV-2 RBD IgG levels peaked at 1 week after the second vaccination, then declined over time and decreased to <10% at 6 months after the second vaccination. Additionally, approximately one third of subjects at 6 months after the second vaccination were seronegative for the Omicron variant. Workers with low anti-SARS-CoV-2 RBD IgG levels also had low neutralizing antibody titers. These data support the active use of boosters for healthcare workers, especially for those with low anti-SARS-CoV-2 RBD IgG levels.

Keywords: Omicron variant; SARS-CoV-2; healthcare worker; mRNA vaccine; neutralizing antibody titer.
 
Back
Top Bottom